NCT06282874 2026-04-09Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal MetastasesGuangdong Association of Clinical TrialsPhase 4 Active not recruiting41 enrolled
NCT04362072 2025-06-11Study of Lorlatinib In People With ALK-positive Non-small Cell Lung CancerPfizerPhase 4 Completed71 enrolled 26 charts